Clinical trials: Pulmonary Resistance
Pneumonia, Ventilator-Associated, Hospital-acquired Pneumonia
Comprehensive Molecular Diagnosis and Management of Hospital- and Ventilator-associated Pneumonia in Norway
HVAPNOR consists of Three work packages: 1. Prospective observational study of Hospital (HAP) - and ventilator-Associated pneumonia (VAP) at 5 hospitals in Norway.
- Conditions
- Pneumonia, Ventilator-Associated, Hospital-acquired Pneumonia, Infectious Disease, Infection, Hospital
- Trial name
- HVAPNOR (NCT04381247)
- Testing
- Molecular diagnostics in HAP and VAP
- Where
- Norway
- Volunteers
- 550 people
- Sponsor
- Vestre Viken Hospital Trust
Preterm Delivery, Atopy
Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health
The aim of the trial is to investigate the effect of daily supplementation with 2.7 grams of long chain n-3 fatty acids during the third trimester of pregnancy.
- Conditions
- Preterm Delivery, Atopy, Metabolic Syndrome
- Trial name
- NCT01353807
- Testing
- Fish oil, Olive oil
- Where
- Denmark
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Centre for Fetal Programming, Denmark
Wegener's Granulomatosis, Churg-Strauss Syndrome
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
- Trial name
- NCT00307593
- Testing
- Infliximab, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Long COVID
Fatigability in Long COVID-19
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility…
- Trial name
- NCT05699538
- Testing
- Minimal-Dose Home-Based Resistance Exercise
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- VA Office of Research and Development
Endotracheal Extubation, Airway Obstruction
Efficacy Study of a Novel Device to Clean the Endotracheal Tube
The purpose of this study is to evaluate the in-vivo efficacy of a novel device (endOclear) for cleaning the endotracheal tube (ETT) lumen from secretions.
- Conditions
- Endotracheal Extubation, Airway Obstruction, Airway Control, Pneumonia, Ventilator-Associated
- Trial name
- NCT01765530
- Testing
- ETT cleaning maneuver
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Massachusetts General Hospital
Tuberculosis
TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB.
- Trial name
- NCT00449644
- Testing
- TMC207, Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
- Where
- 16 sites in Brazil, India and 6 more
- Volunteers
- 208 people
- Sponsor
- Janssen Infectious Diseases BVBA
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Lung Adenocarcinoma
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
Every year in France, 30.000 deaths are due to lung cancer and 39.500 new cases of this disease are diagnosed (INCa 2014). Patients suffering from locally advanced non-small-cell lung cancer (NSCLC), stage IIIa, usually undergo a…
- Trial name
- NOTCH (NCT02898857)
- Testing
- biopsies
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Montpellier
Non-small Cell Lung Cancer
Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected…
- Trial name
- SITRR (NCT02075957)
- Where
- France
- Volunteers
- 192 people
- Sponsor
- University Hospital, Angers
Non-small Cell Lung Cancer
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.
- Trial name
- NCT06634667
- Testing
- third-generation EGFR-TKI combined with anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
Based on the possibilities that both plasma and circulating tumor cells (CTCs) (the "liquid biopsy") may offer, we consider that it could be feasible to longitudinally monitor the genetic evolution and the biologic…
- Trial name
- NCT02771314
- Testing
- AZD9291
- Where
- 13 sites in Greece
- Volunteers
- 48 people
- Sponsor
- Hellenic Oncology Research Group
Hypertension, Pulmonary, Cardiac Failure
Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents
The aim of this study is to examine and compare the effect of Levosimendan and Milrinone administered intravenously and via inhalation respectively in cardiac surgery patients with pulmonary hypertension and right ventricular…
- Conditions
- Hypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
- Trial name
- levos-milr (NCT04718350)
- Testing
- levosimendan at a dose of 6 mcg/kg, milrinone at a dose of 50 mcg/kg
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Aretaieion University Hospital
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
Tuberculosis, Pulmonary
Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis
Background: Drug resistant tuberculosis is a serious public health problem that threatens the health of human life and the development of society and economy.
- Trial name
- PMTforDR-TB (NCT02776150)
- Volunteers
- 3,100 people
- Sponsor
- Beijing Hospital
Asthma
Cell Biology of Steroid Resistant Asthma
The hypothesis is that patients who demonstrate steroid resistant asthma by showing little or no improvement in lung function after a course of oral steroids have different cellular responses to steroids than patients who are…
- Trial name
- NCT00361920
- Testing
- prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Jewish Health
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Chronic Obstructive Pulmonary Disease, Metabolic Syndrome
Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine whether roflumilast can improve metabolic profile and reduce visceral adiposity in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- RAMBO (NCT01701934)
- Testing
- Roflumilast
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Laval University
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
NSCLC, Adjuvant Drug Therapy
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations.
- Conditions
- NSCLC, Adjuvant Drug Therapy, EGFR
- Trial name
- NCT07181499
- Testing
- Befotertinib, Pemetrexed + Carboplatin
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.